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We report the effect of a bovine serum albumin (BSA) conjugate of a synthetic hexasac-
charide (HS) related to the fragment of the capsular polysaccharide (PS) of Streptococcus 
pneumoniae type 14 on the stimulation of innate immune system and the subsequent 
development of a PS-specific antibody response. Glycoconjugate (GC) in the presence 
(GC +  AL) or absence of aluminum hydroxide was administered to mice twice. GC 
increased the number of TLR2-expressing cells and induced the maturation of dendritic 
cells (CD11c+, CD80+ and, MHCII+), which secreted IL-1β, IL-6, and TNFα into the cul-
ture medium. The level of IL-1β, IL-10, IFNγ, and TNFα in the blood increased within 24 h 
after the single GC administration to mice. On day 7, the numbers of splenic CD4+ and 
CD8+ T lymphocytes and B lymphocytes increased. After the second immunization, the 
levels of CD4+ and CD8+ T lymphocytes were lower than in the control, whereas the B 
cell, NK cell, and MHC class II-expressing cell numbers remained enhanced. However, 
of the presence of anti-PS, IgG antibodies were not detected. The addition of aluminum 
hydroxide to GC stimulated the production of GM-CSF, IL-1β, IL-5, IL-6, IL-10, IL-17, 
IFNγ, and TNFα. Anti-PS IgG1 antibody titers 7 days after the second immunization were 
high. During that period, normal levels of splenic CD4+ T lymphocytes were maintained, 
whereas reduced CD8+ T lymphocyte numbers and increased levels of B lymphocytes, 
Abbreviations: BSA, bovine serum albumin; CD, cluster of differentiation; DC, dendritic cell; ELISA, enzyme-linked immu-
nosorbent assay; GC, glycoconjugate; GC + AL, glycoconjugate with aluminium hydroxide; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IFN, interferon; IL, interleukin; MALDI-TOF, matrix-assisted laser desorption/ionization time-
of-flight; MHC class II, major histocompatibility complex class II; PS, capsular polysaccharide; SEAP, secreted alkaline 
phosphatase; Th, T helper; TLR, toll-like receptor; TNF, tumor necrosis factor.
2Akhmatova et al. The Effect of a BSA Conjugate of a Synthetic Hexasaccharide
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 248
NK cells, and MHC class II-expressing cell numbers were observed. Anti-PS IgG levels 
diminished until day 92. A booster immunization with GC + AL stimulated the production 
of anti-PS IgG memory antibodies, which were determined within 97 days. The elucida-
tion of specific features of the effect of the synthetic HS conjugate on the stimulation of 
innate, cell-mediated immunity, and antibody response can favor the optimization of GC 
vaccine design.
Keywords: synthetic hexasaccharide conjugate, dendritic cell, cytokine, antibody, cell-surface molecule
inTrODUcTiOn
Streptococcus pneumoniae is one of the major etiological factors 
of bacterial pneumonia, bacteremia, meningitis, otitis media, and 
other serious pneumococcal childhood and adult diseases (1–5) 
and has a high death rate (6–8). A large number of pneumococ-
cal strains are surrounded by a polysaccharide (PS) capsule. 
According to the chemical structure of the capsule, more than 
90 serotypes of S. pneumoniae were identified (5, 9). Among 
them, 20 serotypes of S. pneumoniae cause approximately 80% of 
diseases (7, 10, 11).
IgG antibodies to capsular PS S. pneumoniae (12) and 
complement-mediated opsonophagocytosis (13–15) have been 
found to be the main effector mechanisms underlying protection 
from pneumococcal infection.
Capsular pneumococcal PSs and oligosaccharides are classified 
as T-independent antigens, which induce the formation of predomi-
nantly low-affinity IgM antibodies (12). One of the mechanisms for 
the induction of the T-dependent IgG immune response to capsular 
PSs or oligosaccharides is their conjugation with a carrier protein 
(12, 16–18). Some oligosaccharides that are conjugated with protein 
induce the formation of antibodies to capsular PSs at a higher level 
than that of traditional PS conjugate vaccines (19).
The mechanism of the development of the immune response 
to T-dependent antigens is presently well characterized (12, 20). 
In contrast, the activation of innate and adaptive immunity under 
the action of glycoconjugates (GCs), consisting of a carbohydrate 
part to which the induction of protective IgG antibodies occurs 
and a T-dependent protein carrier covalently bound to the car-
bohydrate part, remains insufficiently studied. Recently obtained 
data indicate that after processing, the GC in antigen-presenting 
cells (APCs), the peptide component is bound to MHC class II 
and the glycan, is recognized by unique carbohydrate-specific 
CD4+ T cells (21).
It is known that capsular carbohydrates interact with B cells 
through the B cell receptor (BCR), resulting in the proliferation 
and differentiation of B lymphocytes (12). PSs affect dendritic 
cells (DCs) through the specific intracellular adhesion molecule-3 
grabbing non-integrin (SIGN) receptor or the mannose recep-
tor (C-type lectin) (22). The data on the activation of toll-like 
receptors (TLRs) under the action of bacterial capsular PS are 
ambiguous (23, 24). According to Meltzer and Goldblatt, DCs 
did not mature and produced no cytokines under the action of 
bacterial capsular PSs from S. pneumoniae of serotypes 1, 6B, 9N, 
14, 19F, or 23F (24).
The capsular PS of S. pneumoniae serotype 14 consists of 
branched tetrasaccharide repeated units (25) and is weakly 
immunogenic compared to the capsular PSs of other pneumococ-
cal serotypes (26, 27). Most of the investigations were devoted 
to the study of the immunogenic properties of tetrasaccharide, 
which is considered to be the main candidate for inclusion into a 
synthetic multivalent pneumococcal vaccine (28).
The activation of the innate immune system in response 
to protein conjugates of synthetic oligosaccharides has never 
before been studied. It is an important stage for the analysis of 
immunological properties toward the development of a vaccine 
because innate immunity determines the direction, length, and 
effectiveness of the adaptive immune response. For these studies, 
it was necessary to choose the appropriate oligosaccharide that 
met special requirements. The oligosaccharide, as a part of the 
protein conjugate, was required to be immunogenic to allow the 
analysis of the influence of the main innate immune factors on 
the production of specific antibodies and other factors of adap-
tive immunity. In this study, immunologically active branched 
hexasaccharide (HS) β-d-Gal-(1 →  4)-β-d-Glc-(1 →  6)-[β-d-
Gal-(1 → 4)]-β-d-GlcNAc-(1 → 3)-β-d-Gal-(1 → 4)-β-d-Glc was 
chosen (28). It is important to note that HS not only represents 
one repeating unit of PS S. pneumoniae type 14 but also includes 
two additional monosaccharides. This structural fragment bears 
greater similarities to PS S. pneumoniae type 14 compared to 
shorter oligosaccharides and therefore, being a part of the GC, 
initiates an immune response that is closer to the action of the PS 
and conjugated pneumococcal vaccines.
In this work, we studied the effect of a synthetic HS represent-
ing a region of the chain of capsular PS S. pneumoniae serotype 
14 conjugated with BSA. The clinical significance of this S. 
pneumoniae serotype, especially for children, was confirmed by 
epidemiological studies (5, 29).
For the first time, a collection of data is presented on the effect 
of this HS and its conjugate with BSA on the in vitro and in vivo 
activation of TLRs, the maturation of DCs, and the production 
of cytokines in mice immunized with the hexacaccharide con-
jugate both absorbed and unabsorbed on aluminum hydroxide. 
The effect of the GC on the change in the splenic mononuclear 
leukocyte phenotype of immunized mice and its ability to induce 
the production of antibodies to capsular PS is also shown here.
MaTerials anD MeThODs
synthetic hexasaccharide-Bsa conjugate
The HS conjugate [β-Gal-(1  →  4)-β-Glc-(1  →  6)-[β-Gal-
(1 → 4)]-β-GlcNAc-(1 → 3)-β-Gal-(1 → 4)-β-Glc-O-spacer]15-
BSA was prepared by the squarate method and contained, 
FigUre 1 | chemical structure of studied glycoconjugate immunogen.
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according to MALDI-TOF data, on average, 15 HS residues as 
previously described (30, 31) and 19% carbohydrates on a dry 
weight basis (Figure 1). The BSA is often used as a protein carrier 
to design immunogenic GCs and biomolecular systems (32) of 
other types. For conjugation with HS used BSA (Sigma, USA).
The capsular PS was obtained from the laboratory strain of 
S. pneumoniae type 14 #883 isolated April 22, 2012 from a child 
with acute otitis media. The strain was grown in a semisynthetic 
nutrient medium. The isolation of PS included ultrafiltration 
and concentration, an enzyme treatment, phenolic deproteini-
zation, and dialysis. Resulting preparations contained <5% of 
denatured proteins and <1% of nucleic acids, while the major 
portion was carbohydrates. The specificity of PS tested in Rocket 
Immunoelectrophoresis and inhibition ELISA, where PS gave the 
rocket with the hyperimmune rabbit serum to S. pneumoniae type 
14 (in a dose of 1 μg/mL) caused 100% inhibition of the ELISA 
reaction with the same serum at a dilution of 1:6400–1:12800. 
The presence of PS in the preparation was confirmed by NMR 
spectrometry.
animals
BALB/c male mice (n = 30) were used for evaluation of the anti-
body production and CBA female mice (n = 96) were used for 
determination of cell surface molecular expression and cytokine 
production. Mice aged 6–8  weeks were purchased from the 
Scientific and Production Centre for Biomedical Technologies, 
Branch “Andreevka” (Moscow, Russia) and kept in the vivarium 
of the Mechnikov Research Institute for Vaccines and Sera. The 
housing, husbandry, blood sampling, and sacrifice conditions 
conformed to the European Union guidelines for the care and use 
of laboratory animals. The design of experiments was approved 
by the Ethics Committee of Mechnikov Research Institute for 
Vaccines and Sera.
immunization
Mice were immunized intraperitoneally twice (on day 0 and 14) 
with GC in the presence (GC +  AL) or absence of aluminum 
hydroxide (Sigma-Aldrich Co., USA), which served as an adjuvant. 
The single dose of GCs diluted in saline was 10 μg (calculated with 
the reference to carbohydrate). Aluminum hydroxide was added 
in an amount of 25 μL (250 μg) per immunizing dose and stored 
overnight at +4°C. A booster immunization was administered 
on day 92 in the same manner and at the same dose of GC with 
aluminum hydroxide.
Tlrs activation and expression
The expression of TLRs was determined by two methods. First, 
the direct ligand–receptor interaction of the HS, the GC and BSA 
was estimated with THP1-XBlue™-CD14 cells (Invivogen, USA) 
derived from the THP1-XBlue™ cell line of human monocytes 
expressing different pathogen-recognizing receptors, including 
TLRs, and NOD-like receptors (NLRs). THP1-XBlue™-CD14 
cells stably express an NF-κB/AP-1-inducible secreted embryonic 
alkaline phosphatase (SEAP)-reporter gene and human CD14 
gene. TLRs stimulation in THP1-XBlue™-CD14 cells induces 
signaling cascades leading to the activation of NF-κB and AP-1 
and the subsequent production of SEAP. The reporter protein is 
easily detectable and measurable when using QUANTI-Blue™, a 
medium that turns purple/blue in the presence of SEAP.
Hexasaccharide conjugated with BSA (GC), HS, and BSA 
at concentrations of 100  μg/mL were used to estimate SEAP 
activity. The negative control (C−) was phosphate buffered saline 
(PBS). The following substances served as positive controls (C+): 
lipopolysaccharide (LPS) (ligand for TLR4) (Sigma-Aldrich Co., 
USA); CBLB502, denoted as Entolimod (Cleveland Biolabs, Inc.), 
an engineered derivative of a Salmonella flagellin protein that 
induces a spectrum of protective effects upon direct interaction 
and signaling via TLR5; and C12-iE-DAP (Invivogen, USA), an 
acylated derivative of the dipeptide iE-DAP (γ-d-Glu-mDAP) 
that is present in the peptidoglycan of Gram-negative bacilli and, 
particularly, Gram-positive bacteria, and is recognized by the 
intracellular sensor NOD1, which results in NF-κB activation and 
the production of inflammatory cytokines. The positive controls 
were used at a concentration of 1 μg/mL.
Second, the number of TLR2- and TLR4-expressing spleen 
mononuclear cells was determined by flow cytometry (Cytomix 
FC-500, Beckman Coulter, USA with the CXP software) using 
FITC anti-CD282 and PE anti-CD284 monoclonal antibodies 
(eBioscience, USA), respectively. As the cut-off for the positive 
expression was the number of TLR2- and TLR4-positive spleen 
mononuclear cells in non-immunized mice.
cell surface Molecule  
expression on Dendritic cells
Dendritic cells were obtained from mouse bone marrow and 
cultivated in RPMI-1640 with 20 ng/mL granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and 20  ng/mL of interleu-
kine-4 (IL-4). On day 7, GC (50 μg/mL) was added to the culture 
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medium. TNFα at a concentration of 20  ng/mL was used as a 
positive control. Three days after incubation, the DC cell surface 
molecules and cytokine production were determined by flow 
cytometry (Cytomix FC-500, Beckman Coulter, USA with the CXP 
software). The cell population gate was determined by forward and 
side scattering and cell size; 10,000 cells per gate were recorded. The 
Abs that was used included: FITC or PE-conjugated Abs against 
CD34 (clone RAM34, FITC), CD11c (clone HL3, FITC), CD83 
(clone Michel-17, FITC), CD86 (clone PO3.1, PE), CD80 (clone 
16-10A1, FITC), MHCII (I-EK, PE) (clone 14-4-45); all were 
obtained from eBioscience (eBioscience Inc., San Diego, CA, USA).
cell surface Molecule expression on 
splenic Mononuclear cells
Splenocytes were isolated from mice vaccinated with the glycon-
jugate in the absence or in the presence of aluminum hydroxide 
7  days after the first and second immunizations. Single-cell 
suspensions of splenocytes were prepared by mashing the spleen 
with the plunger of a disposable syringe, passing the ground spleen 
through a nylon mesh, and suspending the cells in PBS. Splenic 
single-cell suspensions were stained with phycoerythrin (PE)- or 
fluorescein isothiocyanate (FITC)-conjugated anti-mouse anti-
bodies to: CD3, CD4, CD8, CD19, CD5.2, NK1.1, CD25, CD4/
CD25 (Treg), TCR (T gamma-delta), and I-EK (MHC class II) 
monoclonal antibodies (eBioscience, USA) at 4°C for 30  min. 
Erythrocytes were then lysed with red blood cell lysis buffer 
(BioLegend, USA). After washing with PBS, the samples were 
fixed with a fixation solution (BioLegend, USA) and analyzed by 
flow cytometry (Cytomix FC-500, Beckman Coulter, USA with 
the CXP software). The cell population gate was determined by 
forward and side scattering and cell size; 10,000 cells per gate were 
recorded. Spleen cell suspensions were stained using antibodies 
specific for mouse CD3e-FITC (clone 145-2C11), CD4-FITC 
(clone GK1.5), CD8a-FITC (clone 53-6.7), γδT (clone γδ TCR-PE, 
eBioGL3), CD19-FITC (eBio1D3), CD5-PE (clone 53-7.3) NK.1.1 
(clone PK136) CD25-PE (PC61.5), and MHCII-PE (I-EK) (clone 
14-4-45) obtained from eBioscience or Biolegend (San Diego, CA, 
USA). Treg: Alexa Fluor 405-conjugated anti-mouse CD4 (clone 
RM4-5) was obtained from Caltag Laboratories. Staining with 
anti-FoxP3-FITC conjugated Ab (clone FJK-16s) was performed 
according to the manufacturer’s protocol (eBioscience).
cytokine Production
The level of cytokines in DC supernatants and in mouse serum 
obtained at 2, 4, 8, and 24 h after the intraperitoneal injection of 
GC or GC + AL was determined by the FlowCytomix Mouse Thl/
Th2 10-plex Kit test system containing beads coated with mono-
clonal antibodies to cytokines [GM-CSF, IFNγ, IL-1β, IL-2, IL-4, 
IL-5, IL-6, IL-10, IL-17, and TNFα (eBioscience, USA)] using a 
flow cytometric assay (FC-500, Beckman Coulter, USA).
antibodies to Pneumococcal Ps
Serum PS-specific IgG was detected by ELISA. Blood serum was 
obtained 7, 14, 21, and 28 days after intraperitoneal immuniza-
tion of mice with GC and 7, 14, 21, 28, 61, 92, 93, 96, 99, and 
189 days after GC + AL administration. Blood samples from six 
mice were studied for each time point. A booster immunization 
of GC + AL was carried out on d 92. Anti-PS IgG and subiso-
type (IgG1, IgG2a, IgG2b, IgG3) levels were determined by the 
enzyme-linked immunosorbent assay (ELISA) as previously 
described (30). Specifically, flat-bottom plates (Biochemicals, 
Russia) were coated with a PS preparation from S. pneumoniae 
type 14 (1 μg/well). The presence of the PS in the preparation was 
demonstrated by two-dimensional Nuclear Magnetic Resonance 
(NMR). For secondary antibodies to total IgG, horseradish 
peroxidase-labeled dry diagnostic antibodies to IgG (H  +  L) 
of white mice (Medgamal, Russia) and rabbit anti-mouse per-
oxidase conjugated IgG1 (gamma 1 chain), IgG2a (gamma 2a 
chain), IgG 2b (gamma 2b chain), and IgG3 (gamma 3 chain) 
(Rockland Immunochemicals, Inc., Gilbertsville PA, USA) were 
used. The optical density (OD) was determined using an ELISA 
reader (iMark, Japan) at 450 nm. The antibody titers were defined 
as the dilution of serum giving twice the OD450 for control mice 
(non-immunized) with a cutoff value of 0.2.
statistical analysis
Multiple comparisons of the serum titration data were performed 
by one-way ANOVA for independent samples, which were Tukey 
posttested. Log10-transformed data of titers were used in all 
analyses. The groups that failed normality tests were compared 
using the Mann–Whitney rank sum test for independent sam-
ples. A P value of ≤0.05 was considered statistically significant 
(STATISTICA 8 software).
resUlTs
Toll-like receptor 2 expression
The action of synthetic hexasaccharide (HS) on pathogen- 
recognition cell receptors of the innate immune system was 
evaluated in vitro by the level of SEAP by THP1-XBlue-CD14 cells 
expressing different TLRs and NLRs. In the SEAP assay test, HS, 
GC, and BSA were used at the same concentration (100 μg/mL).
Hexasaccharide enhanced SEAP activity compared to the 
negative control (p = 0.049535), GC (20 μg based on HS), and 
BSA (Figure 2A). LPS, CBLB 502, and C12-iE-DAP, which are 
ligands for TLR4, TLR5, and NOD1, respectively, and served 
as positive control for evaluation of THP1-XBlue-CD14 NF-kB 
reporter cells activation, increased SEAP activity when used at a 
concentration that was 100 times lower (1 μg/mL).
The study of TLR expression on mononuclear leukocytes 
from the spleens of mice immunized with GC and GC +  AL 
demonstrated that the population of TLR2-expressing cells 
increased compared to the non-immunized control animals, 
served as a control on the seventh day after the first immunization 
(Figure 2B). After the second immunization, the level of TLR2-
expressing cells remained constant and differed from the control 
(Figure  2C). GC  +  AL stimulated the population of TLR2-
expressing cells after both the first and second immunization 
to a greater extent than GC (p = 0.009). There were no changes 
in the levels of TLR4-expressing cells (data not presented). The 
expression of TLR2 on spleen cells from immunized mice was 
not the outcome of a ligand–receptor interaction according to the 
data of SEAP cell assay.
FigUre 2 | Toll-like receptors. (a) Direct ligand–receptor interaction. SEAP activity determined using the THP1-XBlue-CD14 human monocytic cell line 
expressing endogenous different types of pathogen-recognition receptors. In the SEAP assay test, HS, GC, and BSA were used at the same concentration  
(100 μg/mL). The negative control (C−) is PBS. The positive controls (C+) are LPS, CBLB502, and C12-iE-DAP, which are ligands for TLR4, TLR5, and NOD1, 
respectively. (B) Cell surface TLR2 molecules on the spleen mononuclear leukocytes (SML) on day 7 after the single intraperitoneal immunization of CBA mice 
(n = 6) with GC or GC + AL (10 μg of carbohydrate per mouse). Non-immunized mice (n = 6) served controls. (c) The same as above 7 days after the second 
immunization (n = 6). TLR2 levels on the SML were determined by flow cytometry. The results of the experiments are presented as box plots. The limits of the boxes 
represent the 25th and 75th percentiles of the results. The enclosed line represents the median (50th percentile), and the bars represent the 10th and 90th 
percentiles. The significance of differences between the groups was determined using the Mann–Whitney Rank Sum test. *P < 0.05.
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Dendritic cells Phenotype  
and cytokine Production
The addition of GC (50 μg/mL) to the culture of immature DCs 
generated from mouse bone marrow resulted in a decrease in 
the level of non-differentiated CD34+ cells and an increase in 
the population of cells expressing the adhesion molecule CD11c, 
the costimulatory molecule CD80, and the antigen presentation 
molecule MHC class II compared to immature DC (p <  0.05) 
(Figure 3A). Thus, in the presence of GC, the phenotype of DCs 
corresponded to that of mature DCs (CD11c+, CD80+, MHC class 
II+); however, except for CD11c-expressing cells, their levels were 
lower than in the presence of TNFα (p < 0.05), which was used as 
a positive control (C+).
Under the action of GC, DCs secreted IL-1β, IL-6, and 
TNFα, into the culture medium with decreasing GM-CSF levels 
compared to immature DCs (C−) (p <  0.05) (Figure  3B). The 
levels of IFNγ, IL-2, IL-4, IL-10, and IL-17 did not differ from 
immature DC; however, the level of IL-5 was higher than the 
negative control.
cytokine Production in Mice
To evaluate cytokine production in  vivo, GC or GC +  AL was 
intraperitoneally administered to mice at a single dose of 10 μg 
based on the carbohydrate. Serum cytokine levels were deter-
mined before GC injection (hour 0) and 2, 4, 8, and 24 h after 
administration (Figure 4).
In response to immunization with GC, IL-1β increased at 
2 h and remained at that level for 24 h (p < 0.05). The effect of 
GC + AL during 4 h was the same, but at 8 h, IL-1β transiently 
increased (p < 0.01). IL-2 did not increase in any of the obser-
vation periods (data not presented). In response to GC, IL-4 
short-term increase was at 4 h (p < 0.05). GC + AL stimulated 
FigUre 3 | Dendritic cell maturation. Dendritic cell precursors obtained 
from mouse bone marrow were incubated with IL-4 and GM-CSF for 6 days. 
On day 7, GC was added to the cell culture in the concentration 50 μg/mL 
and 3 days after incubation determined cell surface molecular expression. 
Non-treated cells served as a negative control (C−). Cells incubated with 
TNFα served as positive controls (C+). (a) Cell surface molecules on the 
dendritic cells. CD34 is a molecule that is found on immature cells, CD11c is 
an adhesion molecule, CD80 and CD86 are costimulatory molecules, CD83 
is a molecule of terminally differentiated dendritic cells, and MHCII is the 
major histocompatibility complex class II. The Abs that used included: FITC 
or PE-conjugated Abs against CD34 (clone RAM34, FITC), CD11c (clone 
HL3, FITC), CD83 (clone Michel-17, FITC), CD86 (clone PO3.1, PE), CD80 
(clone 16-10A1, FITC), MHCII (I-EK, PE) (clone 14-4-45), all obtained from 
eBioscience (eBioscience Inc., San Diego, CA, USA). (B) Cytokine production 
in the culture medium of treated and non-treated cells. The levels of IFNγ, 
IL-2, IL-4, IL-10, and IL-17 did not differ from immature DC. Cell surface 
molecules on the dendritic cells and cytokine levels were determined by flow 
cytometry. The data are shown as the mean ± SD. The significance of 
differences between the groups was determined using the Mann–Whitney 
Rank Sum test. *P < 0.05.
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the production of IL-4 in the interval from 2 to 8 h (p < 0.05). 
IL-5 under the action of GC increased at 8 h (p < 0.01), whereas 
in response to GC + AL remained at a high level in the interval 
from 2 to 24 h (p < 0.01). IL-6 did not change in response to GC, 
whereas the injection of GC + AL increased its production in the 
interval from 2 to 24 h (p < 0.01). IL-10 increased after immuni-
zation with GC and GC + AL from 2 to 24 h (p < 0.01); however, 
GC + AL stimulated higher level of its production. IL-17 under 
the action of GC transiently increased at 8 h (p < 0.05) and in 
the response to GC + AL was in the higher level from 2 to 24 h 
(p < 0.01). TNFα in response to GC and GC + AL increased in 
the period from 2 to 24  h (p <  0.01), but under the action of 
GC + AL was a peak at 4 h (p < 0.01). IFNγ under the action of 
GC and GC + AL increased from 4 to 24 h (p < 0.05) GC + AL 
stimulated the highest production at 24 h (p < 0.01). GM-CSF in 
response to GC increased from 8 to 24 h, GC + AL led to higher 
its production from 4 to 24 h (p < 0.01).
glycoconjugates absorbed and 
Unabsorbed on aluminum hydroxide  
exert Different effects on the levels of  
T and B lymphocytes
The immunization of mice with GC in the presence or absence of 
aluminum hydroxide elicited differences in the surface molecule 
expression levels on mononuclear leukocytes from mouse spleens 
depending on the presence of an adjuvant and immunization 
multiplicity (Figure 5).
A single immunization of mice with GC increased the 
number of T lymphocytes expressing surface molecules CD4 
(T helper) and CD8 (p < 0.05 vs. control and GC + AL) as well as 
B cells expressing CD19 and CD5 markers (p < 0.05 vs. control) 
(Figure 5A). GC + AL exerted no effect on the content of CD4+ 
and CD8+ T cells but favored, to a greater extent, an increase 
in the number of B cells (CD19+, CD5+) and T cells that were 
positive for the IL-2 receptor (CD25+) and the number of cells 
expressing major histocompatibility complex (MHC) class II 
molecules (p < 0.05 vs. control and GC). Both GCs decreased the 
number of γδT lymphocytes but exerted no effect on the number 
of regulatory T lymphocytes (Treg) and natural killers (NK).
After the second immunization of mice with GCs, their effect 
on the cell-mediated immune response changed substantially 
(Figure 5B). The injection of GC decreased the CD4+ T lympho-
cyte numbers (p < 0.05 vs. control), whereas GC + AL exerted 
no effect on the number of T helper cells. Both GCs resulted in a 
decrease in the level of T cells with the expression of CD8+ T cell 
and γδT cell surface molecules (p < 0.05 vs. control). The CD4/
CD8 ratio increased in the presence of aluminum hydroxide due 
to a decrease in CD8+ T cell numbers (for GC, 1.92, whereas for 
GC + Al, 3.36). The number of B cells (CD19+, CD5+) remained 
enhanced (p <  0.05 vs. control) as a response to the repeated 
injection of each GC, and the number of cells expressing MHC 
class II was highest after immunization with GC + AL (p < 0.05 
vs. control and GC). The number of NK cells increased under the 
action of GC and GC + AL.
glycoconjugate absorbed on aluminum 
hydroxide induces a long-term  
igg-antibody response to Ps and 
immunological Memory
Mouse serum PS S. pneumoniae type 14-specific IgG levels were 
measured before and at different time intervals after the two 
intraperitoneal immunizations of mice with GC and GC + AL 
followed by a booster immunization with GC + AL on day 92 
(Figure 6).
FigUre 4 | cytokine production in mice. Mice CBA were immunized with GC or GC + AL (10 μg of carbohydrate per mouse). Serum was collected from mice 
(n = 6 for each time-point) at the indicated hours after immunization. The cytokine levels were determined by flow cytometry. IL-2 level did not increase in any of the 
observation periods (data not presented). The data are shown as the mean ± SD. *P < 0.05; **P < 0.01.
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The first immunization with GC or GC + AL at a single dose 
of 10 μg based on carbohydrate-specific IgG levels did not differ 
from non-immunized mice (day 0) on days 7 and 14 (Figure 6A). 
One week (day 21) following the second immunization with 
GC + AL, IgG levels increased (p = 0.000177) and continued to 
increase until day 28, whereas GC alone did not induce antibody 
production, which was also demonstrated by testing for IgG1 in 
individual mouse sera (Figure 6B).
IgG levels after GC + AL immunization remained high until 
day 61 (47  days after the second immunization) compared 
to the initial level (days 0–14) (p = 0.000205). On day 92, IgG 
levels decreased but remained higher than the initial values 
(p = 0.011659). The individual titers of IgG1 14 days (day 28) after 
the second GC + AL immunization are displayed in Figure 6B. 
The booster immunization GC + AL using GC (dose 10 μg based 
on carbohydrate) was performed on day 92 on a background of 
FigUre 5 | cell surface molecule expression by splenic mononuclear leukocytes. CBA mice were immunized with GC or GC + AL (10 μg of carbohydrate 
per mouse). Non-immunized mice (n = 6) served as a control. T lymphocytes (CD3, CD4, and CD8); B lymphocytes (CD19, CD5); NK; CD25 is the IL-2 receptor on 
T cells and MHC class II were determined by flow cytometry. (a) 7 days after the first immunization (n = 6); CD4/CD8 ratio: GC – 1.08, GC + AL – 1.82. (B) 7 days 
(day 21) after the second immunization (n = 6); CD4/CD8 ratio: GC – 1.92, GC + AL – 3.36. Spleen cell suspensions were stained using antibodies specific for 
mouse CD3e-FITC (clone 145-2C11), CD4-FITC (clone GK1.5), CD8a-FITC (clone 53-6.7), γδT (clone γδ TCR-PE, eBioGL3), CD19-FITC (eBio1D3), CD5-PE (clone 
53–7.3) NK.1.1 (clone PK136) CD25-PE (PC61.5) and MHCII-PE (I-EK) (clone 14-4-45) obtained from eBioscience or Biolegend (San Diego, CA, USA). Treg: Alexa 
Fluor 405-conjugated anti-mouse CD4 (clone RM4-5) was obtained from Caltag Laboratories. Staining with anti-FoxP3-FITC conjugated Ab (clone FJK-16s) was 
performed according to the manufacturer’s protocol (eBioscience). The data are shown as the mean ± SD. Mann–Whitney Rank Sum test. *P < 0.05.
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low IgG levels (Figure 6A). One day later (day 93), the IgG levels 
remained at the initial level, but 4 days later (day 96), the IgG 
titers increased (p = 0.012195) and continued to increase on the 
seventh day (day 99) (p = 0.01148). The rapid generation of IgG 
indicates the formation of immunological memory to PS. The 
activation of immunological memory resulted in a prolonged 
antibody response within 97 days after a booster GC + AL injec-
tion (day 189), and the anti-PS IgG titers remained higher than 
before revaccination (p = 0.031494).
The IgG2a, IgGb, and IgG3 levels after GC + AL immunization 
did not substantially increase (the data are not presented).
DiscUssiOn
Certain success was achieved with the development of synthetic 
vaccines against a number of infectious diseases. Vaccines against 
Haemophilus influenzae type b (33), meningococcus group C 
(34), Staphylococcus (35), and other socially significant infections 
are being developed.
The development of synthetic pneumococcal vaccines is 
aimed at searching for immunogenic oligosaccharides that 
induce, being components of GCs, the production of protective 
antibodies to capsular PSs of etiologically significant serotypes of 
pneumococcus, including S. pneumoniae type 14 (5). The con-
jugates of carrier proteins with some synthetic oligosaccharides 
related to fragments of capsular PSs of various S. pneumoniae 
serotypes were studied as potential vaccines (29).
The production of IgG antibodies to HS conjugated with BSA 
required the presence of an adjuvant and two immunizations, 
after which the high level of antibodies to capsular PS and the for-
mation of immunological memory in response to revaccination 
were observed. Aluminum hydroxide was used as an adjuvant. 
The highest level of antibodies 1:6400–1:12800 in response to HS 
conjugated with BSA and absorbed on aluminum hydroxide was 
revealed in 2 weeks after double immunization. According to our 
data, the titer of IgG antibodies to Prevenar-13 with aluminum 
phosphate, as adjuvant, after double intraperitoneal immuniza-
tion of mice with a dose of 1.1 μg/mouse for PS S. pneumoniae 
type 14 was 1:800–1:1600 in ELISA (data not presented).
It is known that the immune response starts from the activa-
tion of the receptor apparatus of APCs. There are data indicating 
that 23-valent pneumococcal PS vaccine Pneumovax-23 stimu-
lated the expression of TLR2 and TLR4 and that pneumococcal 
conjugate vaccine Prevnar activated TLR2, which resulted in 
FigUre 6 | antibody production. CBA mice were immunized intraperitoneally with GC (white bars) or GC + AL (black bars) (10 μg of carbohydrate per mouse) at 
days 0 and 14 and were boosted on day 92 with the same dose of GC + AL. (a) Anti-PS IgG. Serum samples were collected at the indicated time intervals from 
mice (n = 6) and tested by ELISA using plates coated with PS. Antibody titers were expressed as the dilution giving twice the OD obtained for mice on the day 0. 
The data are shown as the mean ± SEM. (B) IgG1. Individual titers of the anti-PS antibodies on day 28 (day 14 after the second immunization) in BALB/c mice 
vaccinated with a dose of 10 μg in the presence (black points) or absence (white points) of aluminum hydroxide. Each group contained six mice. The data are 
shown as individual data points and mean ± SD. One-way ANOVA and Tukey posttest, *P < 0.05; **P < 0.01; ***P < 0.001.
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an increase in the anti-PS IgG response in mice predominantly 
through IgG2a, IgG2b, and IgG3 rather than IgG1. In the authors’ 
opinion, TLR activation occurred under the action of bacterial 
impurities present in commercial preparations (23). However, in 
a test of transgenic TLR2−/− mice with a defect in the TLR2 gene 
expression, the production of specific IgM under the action of 
PS S. pneumoniae types 3 and 14 was lower than that of wild-
type mice (24). It is notable that TLR2 expression levels were not 
determined.
We showed an increase in the number of cells with TLR2 
expression on mononuclear leukocytes of the spleens of mice 
immunized by synthetic HS conjugated with BSA. The activation 
of TLRs was non-specific and likely occurred under the action 
of cytokines and other “danger signals,” which was confirmed by 
a minor (compared to positive controls) increase in the SEAP 
activity of THP1-XBlue™-CD14 cells affected by HS. Thus, the 
expression of TLR2 on spleen cells from immunized mice was 
not the outcome of a ligand-receptor interaction according to the 
data of SEAP cell assay.
The activation of antigen-specific T cells is controlled by 
signal 1 (TCR) and signal 2 (costimulatory molecules). Signal 3 
is believed to exist in the form of pro-inflammatory cytokines 
produced by APCs, and they directly affect T cells (36). TLRs 
expressed on APCs are responsible for the generation of signal 
2 and signal 3 (37). During vaccination, aluminum hydroxide 
has also been shown to generate signals 2 and 3 (38), i.e., it can 
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compensate for insufficient TLR activation and cytokine produc-
tion to induce T cell activation.
Glycoconjugate induced the maturation of DCs generated 
from mouse bone marrow in  vitro. Mature CD11c+, CD80+, 
and MHC class II+ DCs secreted IL-1β, IL-6, and TNFα into 
the culture medium. However, surface molecule expression and 
cytokine production were lower compared to the positive control 
(TNFα). The level of IL-1β production was higher than that of the 
positive control only if the conjugate absorbed on the aluminum 
hydroxide was added into the DC culture medium.
A wide spectrum of serum cytokines was determined in 
mice after a single administration of GC absorbed on aluminum 
hydroxide, which suggests the activation of various cells of the 
immune system. GC without an adjuvant resulted in the pro-
longed production (from 2 to 24 h) of IL-1β, IL-10, and TNFα 
alone, GM-CSF (from 4 to 24 h), and IFNγ (from 8 to 24 h). In 
this protocol, the levels of IL-6 which is involved in B lymphocyte 
differentiation, antibody-forming cell maturation, and immuno-
globulin production remained unchanged, whereas, IL-4, IL-5, 
IL-17, cytokines increased in a transitory manner and to a lesser 
extent after immunization with the absorbed preparation. The 
preparation absorbed on aluminum hydroxide stimulated an 
increased production of all studied serum cytokines: IL-1β, IL-4, 
IL-6, IL-10, IL-17, GM-CSF, IFNγ, and TNFα. Transient increase 
of IL-1β and TNFα was observed at 8 and 4 h, respectively. In the 
previous study, we revealed that sera obtained at 4 h after the single 
immunization of mice with GC without aluminum hydroxide did 
not possess bactericidal activity and those obtained at 24 h only 
weakly promoted phagocytosis of the live culture of heterologous 
pathogen (Staphylococcus aureus) by leukocytes. GC absorbed on 
aluminum hydroxide increased bactericidal activity of peripheral 
blood leukocytes of mice obtained at 4 h and more intensively at 
24 h after the single immunization (39).
After the second immunization, the GC absorbed on alu-
minum hydroxide resulted in the formation of IgG antibodies 
to capsular PS. In the previous studies, it was shown that the 
hexasaccharide conjugate adsorbed on aluminum hydroxide 
protected immunized mice from S. pneumoniae serotype 14 
(39). Without aluminum hydroxide, the GC did not possess the 
protective properties (39). In this period, against the background 
of normal CD4+ T helper cell numbers, the suppressor effect of 
CD8+ T lymphocytes decreased, the expression of the IL-2 recep-
tor (CD25+) on T lymphocytes increased, the number of B lym-
phocytes increased, and the expression of MHC class II molecules 
on mononuclear leukocytes from the spleen increased. IgG1 was 
predominantly formed, which assumes the polarization of the 
immune response occurs mainly via the Th2 route. In addition to 
its activating effect on Th2 cells, the absorbed GC activated Th1 
cells, producing IFNγ and Th17 cells, leading to IL-17, which is 
involved in the protection from extracellular bacteria, including 
S. pneumoniae (40). The predominant direction of the immune 
response via the Th2 route is probably caused by the presence of 
aluminum hydroxide (41).
cOnclUsiOn
We determined the key stages of the activation of the innate and 
adaptive immune responses in mice by a BSA conjugate of a 
synthetic HS that was related to the fragment of the capsular PS 
of S. pneumoniae type 14. The revealed specific features of GC 
action on the activation of innate and adaptive immunity make 
it possible to enhance their immunogenic properties and to opti-
mize the design of synthetic vaccines. It may also be promising 
to search for efficient adjuvants for oligosaccharide-conjugated 
vaccines.
aUThOr cOnTriBUTiOns
NA  –  planning study, assessment of the immunophenotype of 
dendritic cells and mononuclear leukocytes of mice, statisti-
cal analysis of data. EK  –  a study on the duration of antibody 
response in mice. Evaluation of immune response after booster 
administration to mice, a conjugate with a synthetic hexasaccha-
ride. EA – obtaining mature dendritic cells, evaluating the level 
of cytokines in the supernatant of dendritic cells and in the sera 
of mice vaccinated with conjugated hexasaccharide, adsorbed on 
aluminum hydroxide. NE – summarizing the results, comparison 
with the data of contemporary literature, statistical analysis of the 
results of the study. DL – estimation of the direct ligand-receptor 
interaction of the hexasaccharide, the glycoconjugate and BSA 
was with THP1-XBlue™-CD14 cells derived from the THP1-
XBlue™ cell line of human monocytes expressing different 
pathogen-recognizing receptors, including TLRs, and NOD-like 
receptors. MG – characterization of the capsular polysaccharide 
of S. pneumoniae type 14 and assessment of its ability to rec-
ognize antibodies to the conjugated hexasaccharide in ELISA. 
Elena V. Sukhova  –  synthesis of the hexasaccharide fragment 
of the capsular polysaccharide of S. pneumoniae. Evaluation of 
the immunological activity of the conjugated hexasaccharide in 
ELISA. Dmitry V. Yashunsky – synthesis and characterization of 
the hexasaccharide.
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